PDCD1 and fungal infectious disease: Thus, in addition to understanding the effects of the PD-1 signaling pathway on fungal pathogenesis (reviewed below), it will be essential to ascertain whether the expanding clinical use of checkpoint inhibitors will alter the susceptibility or severity of fungal infections in patients treated with these immunotherapy agents.